UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Can-Fite Reports 2023 Financial Results and Clinical Update RAMAT GAN, Israel, March 28, 2024 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023. Namodenoson Drug Candidate: 2. Can-Fite Broadens its Strong Intellectual Property (IP) for NASH (MASH): Received Patent ...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”. This invention addresses the use of Namodenoson for the reduction of l ...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the pancreatic cancer indication of Can-Fite. During 2021, Can-Fite entered into an exclusive distribution agreement for Piclidenoson with Switzerland-based Ewopharma AG for the treat ...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Journal of the European Academy of Dermatology and Venereology (EADV) published an article titled “Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1)”. EADV is a top ranked peer reviewed j ...

Exhibit 99.1 Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update Advanced liver cancer patient in prior Phase II study remains cancer-free 6.9 years after starting treatment with Namodenoson PETACH TIKVA, Israel, November 30, 2023 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results for the nine months ended Sep ...

PETACH TIKVA, Israel, June 1, 2023 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced financial results for the three months ended March 31, 2023. Pivotal Phase 3 Liver Cancer Study—Can-Fite's ongoing pivotal Phase 3 liver cancer study is designed to assess Namodenoson in the treatment of patients with advanced hepatocellular carcinoma (HCC) and ...

Exhibit 99.1 PETACH TIKVA, Israel, March 30, 2023 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the year ended December 31, 2022. PICLIDENOSON Pivotal Phase III Psoriasis Registration Plan for Piclidenoson Submitted to EMA – Can-Fite submitted a market registration plan to the European Medicines Agency (EMA) for Picliden ...

● any patents that are issued may not provide meaningful protection; ● we may not be able to develop additional proprietary technologies that are patentable; ● other companies may challenge patents licensed or issued to us; ● other companies may independently develop similar or alternative technologies, or duplicate our technologies; Washington, D.C. 20549 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or Commission File No. 001-36203 (Name, Telephone, E-mail and/or F ...

Financial Performance - Revenues for the nine months ended September 30, 2022 were $0.61 million, a decrease of $0.04 million, or 6.1%, compared to $0.65 million for the same period in 2021[9] - Research and development expenses for the nine months ended September 30, 2022 were $5.31 million, a decrease of $1.44 million, or 21.3%, compared to $6.75 million for the same period in 2021[10] - General and administrative expenses for the nine months ended September 30, 2022 were $2.31 million, a decrease of $0.40 million, or 14.7%, compared to $2.71 million for the same period in 2021[11] - Net loss for the nine months ended September 30, 2022 was $7.15 million, compared with a net loss of $8.50 million for the same period in 2021, reflecting a decrease in losses[13] - As of September 30, 2022, cash and cash equivalents and short-term deposits totaled $10.79 million, down from $18.90 million at December 31, 2021[14] Product Development and Clinical Trials - Can-Fite's pivotal Phase III liver cancer study for Namodenoson is open for enrollment of approximately 450 patients diagnosed with HCC[4] - The latest Phase III findings for Piclidenoson showed a significantly better tolerability profile compared to Otezla, with GI-related adverse events at 1% for Piclidenoson versus 6% for Otezla[5] - Can-Fite is preparing to submit the pivotal Phase III psoriasis study protocol to the FDA and EMA for Piclidenoson[6] - The canine osteoarthritis market is projected to reach $3 billion by 2028, with Piclidenoson set to enter efficacy studies in this area[7] Strategic Partnerships and Market Position - Can-Fite maintains full distribution rights for Piclidenoson and Namodenoson in the U.S., the largest market in the world, while evaluating strategic partnerships[8] - Can-Fite emphasizes the importance of strategic partnerships and corporate collaborations[25] Risks and Challenges - The company acknowledges a history of losses and the need for additional capital to fund operations[25] - Risks include uncertainties in cash flows and the ability to meet working capital needs[25] - The initiation and results of preclinical studies and clinical trials are critical for advancing product candidates[25] - Regulatory approvals and the timing of filings are essential for product candidate development[25] - The company faces competition and risks related to the COVID-19 pandemic and geopolitical issues[25] - There are risks associated with not meeting NYSE American continued listing requirements[25] - Investors are cautioned against placing undue reliance on forward-looking statements due to inherent uncertainties[25] Forward-Looking Statements - Can-Fite's forward-looking statements include expectations regarding product development, financial condition, and business strategies[25] - The company must maintain intellectual property rights to protect its product candidates[25]